We can’t show the full text here under this license. Use the link below to read it at the source.
Effect of glucagon‐like peptide 1 receptor agonists on systolic blood pressure in patients with obesity, with or without diabetes: A systematic review and network meta‐analysis
Glucagon-like peptide 1 receptor agonists and their effects on top blood pressure in obese patients with and without diabetes
AI simplified
Abstract
GLP-1 receptor agonists are associated with a significant reduction in (SBP) of -3.14 mmHg in patients with obesity.
- Patients without diabetes experienced a greater reduction in SBP (-3.80 mmHg) compared to those with diabetes (-2.13 mmHg).
- Among patients with diabetes, liraglutide at doses less than 2 mg resulted in a notable SBP reduction of -3.78 mmHg.
- Efpeglenatide at doses of 6 mg or less showed the highest SBP reduction of -6.00 mmHg in patients without diabetes.
- The change in SBP appears to be only slightly influenced by the specific drug-dose combination.
- Reductions in SBP may be related to the amount of weight loss experienced by patients.
AI simplified
Key numbers
-3.14 mmHg
Mean Reduction
Overall reduction in for all patients receiving GLP-1RAs.
-3.80 mmHg
Reduction in Patients Without Diabetes
Reduction in for patients without diabetes treated with GLP-1RAs.
-2.13 mmHg
Reduction in Patients With Diabetes
Reduction in for patients with diabetes treated with GLP-1RAs.